Vikas Kushwaha
Overview
Explore the profile of Vikas Kushwaha including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
73
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kushwaha V, Saini S, Capalash N
Microb Pathog
. 2024 Nov;
198:107138.
PMID: 39571830
The majority of anti-leishmanial drugs used for treating trypanosomatid parasites help to reduce human morbidity and mortality. However, parasites have developed drug resistance, which has made it challenging to treat...
2.
Murthy P, Tewari P, Mandal P, Kushwaha V
Acta Parasitol
. 2023 Nov;
68(4):929-936.
PMID: 37935895
Purpose: In search of a vaccine for the control of human lymphatic filariasis (LF) caused by Wuchereria bancrofti, Brugia malayi and B. timori, we identified three parasite-specific potential candidates: the...
3.
Kushwaha V, Capalash N
Acta Trop
. 2023 Mar;
241:106867.
PMID: 36878386
Visceral leishmaniasis is neglected tropical protozoan disease caused by Leishmania donovani and are associated with high fatality rate in developing countries since prophylactic vaccines are not available. In the present...
4.
Kushwaha V, Capalash N
Mol Biochem Parasitol
. 2022 Aug;
251:111510.
PMID: 35988745
TriTryp diseases (Leishmaniasis, Human African Trypanosomiasis (HAT), and Chagas disease) are devastating parasitic neglected tropical diseases (NTDs) that affect billions of people in developing countries, cause high mortality in humans,...
5.
Kushwaha V, Kaur S
Acta Trop
. 2021 Aug;
224:106117.
PMID: 34464587
Coinfection is less commonly observed in individuals around the world, yet it is more common than the single infection. Around 800 million people worldwide are infected with helminths as a...
6.
Kushwaha V, Kaur S
Biologicals
. 2021 Jul;
72:18-26.
PMID: 34229924
Coinfection of Leishmania with bacteria, viruses, protozoans, and nematodes alter the immune system of the host, thereby influencing the disease outcomes. Here, we have determined the immunogenic property and protective...
7.
Verma S, Joseph S, Verma R, Kushwaha V, Parmar N, Yadav P, et al.
Vaccine
. 2020 Jun;
38(32):5076.
PMID: 32517851
No abstract available.
8.
Kushwaha V, Sahasrabuddhe A, Murthy P
Acta Parasitol
. 2020 Jun;
65(4):990-994.
PMID: 32500507
Purpose: We recently identified disorganized muscle protein-1 of Brugia malayi (DIM-1bm) as a vaccine candidate for human lymphatic filariasis. The present study was aimed at investigating the localization of DIM-1bm...
9.
Saeed M, Kushwaha V, Faisal S, Verma R, Ahmad I, Mustafa H, et al.
Protein Pept Lett
. 2020 Feb;
27(9):841-850.
PMID: 32096736
Background: Lymphatic Filariasis (LF) is one of the incapacitating and mosquito-borne sicknesses that on progression may prompt a few recognizable types of clutters like extreme lymphedema, hydrocele, and elephantiasis. Methods:...
10.
Kushwaha V, Rastogi S, Pandey M, Saxena K, Khatoon S, Rawat A, et al.
Curr Top Med Chem
. 2019 Jun;
19(14):1252-1262.
PMID: 31218959
Background: Lymphatic filariasis (LF) is a parasitic disease that causes permanent disability (elephantiasis). Currently used antifilarial drugs are failing to control LF and there is resurgence in some areas. Looking...